MA44408A - Méthode de traitement de la réaction du greffon contre l'hôte (gvd) - Google Patents

Méthode de traitement de la réaction du greffon contre l'hôte (gvd)

Info

Publication number
MA44408A
MA44408A MA044408A MA44408A MA44408A MA 44408 A MA44408 A MA 44408A MA 044408 A MA044408 A MA 044408A MA 44408 A MA44408 A MA 44408A MA 44408 A MA44408 A MA 44408A
Authority
MA
Morocco
Prior art keywords
gvd
versus host
host reaction
treating graft
graft
Prior art date
Application number
MA044408A
Other languages
English (en)
Inventor
John E Ford
Jessica A Sachs
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA44408A publication Critical patent/MA44408A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044408A 2016-03-14 2017-03-13 Méthode de traitement de la réaction du greffon contre l'hôte (gvd) MA44408A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14

Publications (1)

Publication Number Publication Date
MA44408A true MA44408A (fr) 2019-01-23

Family

ID=58448610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044408A MA44408A (fr) 2016-03-14 2017-03-13 Méthode de traitement de la réaction du greffon contre l'hôte (gvd)

Country Status (12)

Country Link
US (1) US20200002422A1 (fr)
EP (1) EP3430052A2 (fr)
JP (2) JP2019508448A (fr)
CN (2) CN116327920A (fr)
AU (1) AU2017234009B2 (fr)
BR (1) BR112018068628A2 (fr)
CA (1) CA3017743A1 (fr)
EA (1) EA201892071A1 (fr)
IL (1) IL261750B2 (fr)
MA (1) MA44408A (fr)
MX (1) MX2018011169A (fr)
WO (1) WO2017160699A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468597A1 (fr) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
WO2019157158A2 (fr) 2018-02-08 2019-08-15 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour la transplantation de cellules souches hématopoïétiques allogéniques
EP4142755A4 (fr) * 2020-04-27 2024-06-12 Children's Hospital Medical Center Posologie de précision

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0808367B1 (fr) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Adressines vasculaires de muqueuses et leurs utilisations
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
MXPA04011465A (es) 2002-05-24 2005-02-14 Millennium Pharm Inc Inhibidores de ccr9 y metodos de uso de los mismos.
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
SG10201801337WA (en) * 2009-03-20 2018-03-28 Amgen Inc Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2012151247A2 (fr) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION POUR UN ANTICORPS ANTI-α4β7
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
CN104024276A (zh) * 2012-06-21 2014-09-03 卡姆普根有限公司 Lsr抗体及其用于癌症治疗的用途
BR112017003546A2 (pt) * 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CN109153721A (zh) * 2016-03-14 2019-01-04 千禧制药公司 治疗或预防移植物抗宿主疾病的方法

Also Published As

Publication number Publication date
IL261750B2 (en) 2024-07-01
CA3017743A1 (fr) 2017-09-21
WO2017160699A3 (fr) 2017-11-23
MX2018011169A (es) 2018-12-06
EA201892071A1 (ru) 2019-03-29
IL261750A (en) 2018-10-31
AU2017234009B2 (en) 2024-06-06
EP3430052A2 (fr) 2019-01-23
AU2017234009A1 (en) 2018-09-27
CN109071660A (zh) 2018-12-21
WO2017160699A2 (fr) 2017-09-21
JP2019508448A (ja) 2019-03-28
KR20180120706A (ko) 2018-11-06
IL261750B1 (en) 2024-03-01
JP2022163078A (ja) 2022-10-25
US20200002422A1 (en) 2020-01-02
BR112018068628A2 (pt) 2019-07-30
CN116327920A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
HK1245308A1 (zh) 聚丙內酯生產方法和系統
HK1245762A1 (zh) 丙烯酸生產方法
MA46954A (fr) Méthodes de traitement d'états inflammatoires
DK3204015T3 (da) Forbindelser og fremgangsmåder til inhibition af hao1-genekspression (hydroxysyre oxidase 1 (glycolat oxidase))
IL266785A (en) A method for the directed modification of double-stranded DNA
GB2551732B (en) Method of processing wafer
GB2551964B (en) Method of treating biomass to remove RNA
RS64489B1 (sr) Kompletan postupak za tretman biološkog otpada
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
IL265696A (en) Methods for treating female infertility
PH12016500963A1 (en) Novel dgat2 inhibitors
ZA201903408B (en) Process for purification of pyrazolpyridazines
IT201600105178A1 (it) Procedimento per la produzione di dieni
HK1247818A1 (zh) 治療疾病的方法
FR3039368B1 (fr) Procede de traitement cosmetique
MA44408A (fr) Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
PL3283097T3 (pl) FSH do leczenia niepłodności
SG11201608513WA (en) Novel purification process of gonadotropin
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
SG11201802755WA (en) Process for purification of methyl methacrylate
EP3260535A4 (fr) Procédé de production en masse d'ovules de souris faisant appel à un nouveau traitement d'induction de la superovulation
DK3506994T3 (da) Kombineret proces for opsamling af syregasser og vandudvinding
MA45245A (fr) Méthode de traitement de maladie intestinale inflammatoire
EP3476954A4 (fr) Procédé de traitement thermique d'une pièce a usiner en forme de tige